DOCSLIB.ORG

The Tetracyclines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Tetracyclines Baran Lab T h e T e t r a c y c l i n e s D. W. Lin Cl HO Me NMe2 OH NMe2 The tetracycline family of antibiotics H H H H OH OH The natural products H N NH2 Cl HO Me NMe2 HO Me OH NMe2 H H H H OH OH OH OH OH O HO O O OH OH O HO O O clomocycline methacycline (rondomycin) NH2 NH2 (megaclor) 1963 1965 OH OH OH O HO O O OH O HO O O Me OH NMe2 NMe2 NMe2 chlortetracycline oxytetracycline H H H H OH OH (aureomycin) (terramycin) 1948 1949 NH2 NH2 HO Me NMe2 Cl HO NMe2 OH OH H H H H OH O HO O O OH O HO O O OH OH doxycycline minocycline NH NH (vibramycin) (minocin) 2 2 1967 1972 OH OH OH O HO O O OH O HO O O NMe2 NMe2 H H tetracycline demethylchlortetracycline OH (achromycin) (declomycin) O H 1953 1957 Me N NH2 N H OH Me Me OH O HO O O Semisynthetic derivatives on the market t-butylglycylamidominocycline (tigilcycline) 1993 HO Me OH NMe2 HO Me OH NMe2 H H H H (Phase III clinical trials in progress) OH OH H H Cl HO Me OH NMe2 N N 5 7 6 5a 4a 4 3 OH OH OH 8 OH O HO O O N OH O HO O O HN D C B A 2 9 NH2 4 12a rolitetracycline limecycline 10 11 12 1 (reverin) (tetralysal) H2N CO2H OH O HO O O 1958 1961 Notation I. Chopra, M. Roberts. Microbiol. Mol. Biol. Rev. 2001, 65, 232. 1 Baran Lab T h e T e t r a c y c l i n e s D. W. Lin Discovery and The Dawn of Semisynthetic Antibiotics HO Me OH NMe2 H H OH NH2 OH OH O HO O O Cl HO Me NMe2 H H OH terramycin NH2 OH OH O HO O O aureomycin Bayer Pharmaceuticals Benjamin Duggar University of Missouri The first tetracycline antibiotic discovered, aureomycin was isolated in 1948 from a Missouri The Nobel Prize Committee soil sample by Lederle R. B. Woodward Laboratories. The Lederle team was led by Benjamin Duggar - a About the same time as the Lederle discovery of aureomycin, Pfizer was consultant who was a 73-year-old scouring the globe for new antibiotics. Soil samples were collected from emeritus professor of botany who jungles, deserts, mountaintops, and oceans. But ultimately terramycin was had recently retired from the isolated in 1949... from a soil sample collected on the grounds of a factory in University of Missouri! As Jie Terre Haute, Indiana, owned by Pfizer! Jack Li cracks, "Your greatest discovery could happen in your retirement." From the beginning, terramycin was a molecule enveloped in controversy. It was the subject of the first mass-marketing campaign by a modern About Lederle Labs: pharmaceutical company. Pfizer advertised the drug heavily in medical Lederle Labs was founded in journals, eventually spending twice as much on marketing as it did to discover 1902 in an old farmhouse on the and develop terramycin. Still, it turned Pfizer - then a small company - into a Pearl River in New York. pharmaceutical giant. Aureomycin was one of many lifesaving products developed by Pfizer and R.B. Woodward collaborated to determine the structure of Lederle, including vaccines for terramycin, succeeding for the most part in 1952 (JACS 1953, 75, 5455). The polio and smallpox. It is now a stereochemistry at C was revised after X-ray crystallography and NMR part of Wyeth Pharmaceuticals. 4a studies in the 1960's (JACS 1965, 87, 134; JACS 1963, 85, 851). Ebay Ad for aureomycin as additive in cattle feed J. J. Li. "A History of Drugs and Their Discoverers." Pfizer Intranet Magazine. March-April 2004. 2 Baran Lab T h e T e t r a c y c l i n e s D. W. Lin Big Pharma Behaving Badly: In 1955, Conover Now, Back to Actual Science discovered that hydrogenolysis of aureomycin gives a deschloro product that is just as active as the original Biosynthesis and Biological Activity: Tetracyclines are polyketide antibiotics, product. This proved for the first time that chemically- biosynthesized in a fashion similar to that of fatty acids, erythromycin and a host of modified antibiotics could have biological activity. Within a other antibiotics. Tetracyclines are produced naturally by Streptomyces few years, a number of semisynthetic tetracyclines had aureofaciens (T. Nakano, et al. Biosci. Biotechnol. Biochem. 2004, 68, 1345.). entered the market, and now most antibiotic discoveries are of novel active derivatives of older compounds. Tetracyclines bind to the bacterial ribosome, preventing the binding of aminoacyl- tRNA to the ribosomal A site. This prevents bacterial protein translation (I. Chopra, Conover's discovery, however, provoked further controversy M. Roberts. Microbiol. Mol Biol. Rev. 2001, 65, 232.). for tetracycline. Pfizer became embroiled in a patent dispute with American Cyanamid, which owned the rights to The Challenge to Synthetic Chemists: Muxfeldt and colleagues outline the basic aureomycin (the starting material for Conover's procedure obstacles to achieving a total synthesis of any of the natural tetracyclines: to make tetracycline). Pfizer and American Cyanamid eventually settled the dispute out of court when they Stereochemical Complexity. There are up to five contiguous asymmetric centers realized that neither company held truly exclusive rights to (terramycin) which must be established. the drug, and agreed to cooperate on selling the drug in order to drive off competitors trying to enter the tetracycline Chemical Sensitivity. For the 6-methyl-6-hydroxy tetracyclines, mild acid rapidly market. At one point, Pfizer employed a private decective catalyzes dehydration, ketalization and a retro-aldol to produce the lactone below. to tap the phones of Bristol-Meyers, a competitor seeking to Mildly basic conditions results in deprotonation of the C5 and C6 hydroxyls, enter the tetracycline market! Bristol-Meyers agreed to About.com initiating a cascade of events which leads to decomposition of the molecule. overlook this brazen act in exchange for a share of the Finally, the C4 stereocenter is readily epimerized upon exposure to acetic acid or Lloyd Conover aqueous buffers. tetracycline market. Eventually five companies colluded in Pfizer order to maintain artificially high prices for tetracycline. However, the Federal Trade Commission stepped in after several years, finding Pfizer and company guilty of patent HO Me OH NMe2 Me NMe2 fraud and anti-trust violations, and broke up the monopoly. H H H OH OH Legal issues aside, for this discovery Lloyd Conover is now in the American acid Inventors' Hall of Fame, alongside Thomas Edison and the Wright brothers. O NH2 NH2 U.S. Federal Trade Commission, "Anticipating the 21st Century: Competition OH OH Policy in the New High-Tech, Global Marketplace". OH O HO O O OH OH O O O base M. Mintz. "Golden Ox of Antitrust." The Nation 14 April 1969, Vol. 208, Issue 15. acid pp. 467-468. O Cl HO Me NMe2 H HO Me NMe2 HO Me OH NMe2 H H H H H H OH OH OH COOH H2, Pd/C HO Me NH2 MeOH/ NH2 NH2 COOH dioxane OH OH OH OH O HO O O OH O HO O O OH O HO O O Conover, L.H. 1955. U.S. Patent No. 2,699,054. H. Muxfeldt, et al. J. Am. Chem. Soc. 1979, 101, 689. 3 Baran Lab T h e T e t r a c y c l i n e s D. W. Lin Woodward's First Total Synthesis of a Biologically-Active Tetracycline, 6- O O Demethyl-6-deoxytetracycline. Cl Cl MeO OMe CO Me L.H. Conover, et al. J. Am. Chem. Soc. 1962, 84, 3222. (Initial communication) CO Me (2 eq.) 2 R.B. Woodward. Pure Appl. Chem. 1963, 6, 561. (A personal account) 2 J.J. Korst, et al. J. Am. Chem. Soc. 1968, 90, 439. (Full article) then NaH (4 eq.), OH (i) O then MeOH (1 eq.), rt --> 80 oC OMe O OH OMe O OMe O O O 45% NaH CO2Me intermolecular condensation outcompetes intramolecular! DMF OMe OMe (ii) O OMe Triton-B MeOH is essential to suppressing the kinetically Cl dioxane-MeOH Cl OMe o favorable intramolecular condensation and OMe OMe O 50-70 C permitting the intermolecular condensation with NaH CO2Me DMF 88% the oxalate prior to formation of the desired 55% tricycle. In the absence of MeOH, Woodward observed formation of the intramolecular product OH O O first, followed by condensation onto the oxalate OMe OH O CO2Me (i) AcOH/ to form the five-membered ring shown: CO2Me CO2Me H2SO4 Cl O (ii) H2SO4 Cl CO Me CO Me 2 MeOH/CHCl3 2 CO2Me n OMe 44% OMe AcOH/HCl H CO2 Bu (i) H2, 200 psi (i) NaOH H2O Mg(OMe)2 OH o O Pd/C CO2Me H2O 90 C toluene o AcOH, 30 oC 100 C OMe O OH 73% OMe O OH reflux 52% (ii) H SO (ii) I , AcOH; 2 4 CO2Me 2 MeOH/CHCl Cl CO nBu 3 then Cl2 in AcOH 2 Cl NMe2 93% OMe (iii) HF, neat o H H (i) NHMe2, -10 C; 63% over 3 steps o n (ii) NaBH4, -70 C CO2 Bu Cl Cl H SO O 69% CO2H 2 4 CO Me OH MeOH/CHCl 2 3 OMe O OH OMe O OH reflux 66% The thermodynamically more favorable diastereomer is formed OMe O OMe O exclusively in this step, with the carboxyamino substituent assuming an equatorial position and thus establishing the cis relationship of Chlorination blocks the para the bridgehead hydrogens.
Load more

Recommended publications
  • Erythromycin Versus Tetracycline for Treatment of Mediterranean Spotted Fever
    Arch Dis Child: first published as 10.1136/adc.61.10.1027 on 1 October 1986. Downloaded from Archives of Disease in Childhood, 1986, 61, 1027-1029 Erythromycin versus tetracycline for treatment of Mediterranean spotted fever T MUNOZ-ESPIN, P LOPEZ-PARtS, E ESPEJO-ARENAS, B FONT-CREUS, I MARTINEZ- VILA, J TRAVERIA-CASANOVA, F SEGURA-PORTA, AND F BELLA-CUETO Hospital de Sant Llatzer, Terrassa, Clinica Infantil del Nen Jesus, Sabadell, and Hospital Mare de Deu de la Salut, Sabadell, Barcelona, Spain SUMMARY Eighty one children aged between 1 and 13 years participated in a randomised comparative trial of tetracycline hydrochloride and erythromycin stearate for treatment of Mediterranean spotted fever. Both therapeutic regimens proved effective, but in patients treated with tetracycline both clinical symptoms and fever disappeared significantly more quickly. Likewise, when those patients who began treatment within the first 72 hours of illness are considered the febrile period had a significantly shorter duration in the group treated with tetracycline. One patient was switched to tetracycline because there was no improvement of clinical manifestations, with persistence of fever, myalgias, and prostration, after receiving eight days of treatment with erythromycin. These results suggest that tetracyclines are superior to erythromycin in the treatment of Mediterranean spotted fever. copyright. Mediterranean spotted fever is an acute infectious were not included in the trial; neither were those disease caused by Rickettsia conorii. During the
    [Show full text]
  • Use of Antibiotics to Prevent Calf Diarrhea and Septiceinia
    PEER REVIEWED Use of Antibiotics to Prevent Calf Diarrhea and Septiceinia Peter D. Constable, BVSc, PhD, DACVIM Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802 Abstract l'oxytetracycline (0.15 to 6.0 mg/lb [0.32 to 13.2 mg/kg] au 24 h, per os) sont efficaces dans le traitement de la This article reviews studies related to the use of diarrhee chez les veaux et permettent un accroissement antimicrobial agents to prevent calf diarrhea and septi­ du taux de croissance des veaux nourris au lait. De cemia, and discusses whether prophylactic administra­ plus, la chlortetracycline permet la diminution du taux tion of antibiotics in neonatal calves is effective and de mortalite lorsque administree chez les veaux indicated. Orally administered chlortetracycline, oxytet­ nouveau-nes pour prevenir la diarrhee. 11 n'y a pas racycline, tetracycline and neomycin have label claims d'antibiotiques qui promettent de prevenir la in the US for the "control" or "aid in the control" of calf septicemie chez les veaux. Paree qu'il ne semble pas diarrhea caused by bacteria susceptible to the antibi­ exister d'etudes sur l'efficacite de la tetracycline et de otic. Chlortetracycline and oxytetracycline (0.15 to 6.0 la neomycine et parce que !'utilisation hors homologa­ mg/lb [0.32 to 13.2 mg/kg], q 24 h, PO) are efficacious tion des medicaments. n'est pas permise pour la for preventing calf diarrhea and increasing growth rate prevention routiniere des maladies ou !'augmentation in milk-fed calves, and chlortetracycline (3 mg/lb [7 mg/ du taux de croissance et du taux de conversion kg], q 12 h, PO) is efficacious for decreasing mortality alimentaire, selon le code de l'AMDUCA de 1994, seule when administered to prevent diarrhea in neonatal !'administration orale de chlortetracycline et calves.
    [Show full text]
  • Long-Term Use of Spironolactone for Acne in Women: a Case Series of 403 Patients
    Long-term use of spironolactone for acne in women: A case series of 403 patients Vaibhav Garg, BS,a JulianaK.Choi,MD,PhD,b William D. James, MD,b and John S. Barbieri, MD, MBAb Philadelphia, Pennsylvania Background: There are limited data regarding the long-term outcomes of spironolactone use for women with acne and its effect on truncal acne. Objective: To comprehensively describe outcomes of patients treated with spironolactone in routine clinical practice, including long-term outcomes. Methods: We performed a retrospective case series of 403 adult women treated for acne with spironolactone at an academic medical center between 2008 and 2019. Rates of objective, as assessed by Comprehensive Acne Severity Scale scores, and subjective acne clearance were evaluated, as well as rates of treatment discontinuation, dosage changes, and drug survival. Logistic regression was used to assess for association between incidence of menstrual adverse effects and combined oral contraceptive use. Results: As evaluated by Comprehensive Acne Severity Scale scores, at the first follow-up, 75.5%, 84.0%, and 80.2% of patients with available data had reduction or complete clearance of acne on the face, chest, and back, respectively. The mean drug survival was 470.7 days. Menstrual adverse effects were less common among those using combined oral contraception (odds ratio, 0.23; 95% confidence interval, 0.11-0.50). Limitations: This study was conducted at a single academic medical center. Conclusions: Spironolactone improves clinical outcomes and is well tolerated for many adult women with acne using it for an extended duration. ( J Am Acad Dermatol 2021;84:1348-55.) Key words: acne; acne vulgaris; birth control pill; combined oral contraceptive; comprehensive acne severity scale; oral antibiotics; outcomes; spironolactone.
    [Show full text]
  • Prednisolone / Neomycin / Tetracycline For- Mulation
    SAFETY DATA SHEET Prednisolone / Neomycin / Tetracycline For- mulation Version Revision Date: SDS Number: Date of last issue: 25.08.2020 3.6 09.04.2021 407521-00015 Date of first issue: 07.01.2016 SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1 Product identifier Trade name : Prednisolone / Neomycin / Tetracycline Formulation 1.2 Relevant identified uses of the substance or mixture and uses advised against Use of the Sub- : Veterinary product stance/Mixture 1.3 Details of the supplier of the safety data sheet Company : MSD 20 Spartan Road 1619 Spartan, South Africa Telephone : +27119239300 E-mail address of person : [email protected] responsible for the SDS 1.4 Emergency telephone number +1-908-423-6000 SECTION 2: Hazards identification 2.1 Classification of the substance or mixture Classification (REGULATION (EC) No 1272/2008) Skin sensitisation, Category 1 H317: May cause an allergic skin reaction. Reproductive toxicity, Category 1A H360D: May damage the unborn child. Effects on or via lactation H362: May cause harm to breast-fed children. Short-term (acute) aquatic hazard, Cate- H400: Very toxic to aquatic life. gory 1 Long-term (chronic) aquatic hazard, Cat- H410: Very toxic to aquatic life with long lasting egory 1 effects. 2.2 Label elements Labelling (REGULATION (EC) No 1272/2008) Hazard pictograms : Signal word : Danger Hazard statements : H317 May cause an allergic skin reaction. H360D May damage the unborn child. H362 May cause harm to breast-fed children. H410 Very toxic to aquatic life with long lasting effects. 1 / 23 SAFETY DATA SHEET Prednisolone / Neomycin / Tetracycline For- mulation Version Revision Date: SDS Number: Date of last issue: 25.08.2020 3.6 09.04.2021 407521-00015 Date of first issue: 07.01.2016 Precautionary statements : Prevention: P201 Obtain special instructions before use.
    [Show full text]
  • Staining and Hypoplasia of Enamel Caused by Tetracycline: Case Report P
    PEDIATRIC DENTISTRY/Copyright © 1987 by The American Academy of Pediatric Dentistry Volume 9 Number 3 Staining and hypoplasia of enamel caused by tetracycline: case report P. Fleming, BDentSc, FDS C.J. Witkop, Jr., DDS, MS W.H. Kuhlmann, DDS, MSD Abstract Case Report Staining of developing teeth due to tetracycline therapy A 23-year-old white male requested restoration of has been publicized widely. However, the ability of tetracy- his stained and hypoplastic anterior teeth (Fig 1). A clines to cause hypoplasia of enamel has not been accepted history revealed that between 2 and 3 years of age he had universally. This is a case report of enamel hypoplasia and received extensive tetracycline therapy for tonsillitis. staining presumably caused byahigh dosage of'tetracy'dines in There was no history of a prolonged fever at the time of childhood. Restoration of the teeth with bonded composite the illness. resins produced an esthetic result. -UK Schwachman and Schuster (1956) were the first to report unsightly staining of teeth due to tetracycline administered during the period of tooth formation in children with cystic fibrosis. This observation was con- y firmed by Zegarelli et al. (1961) who noted staining of the teeth in 38 of 52 cystic fibrosis patients who had been ijgj treated with large doses of antibiotics, frequently tetracy- .^••W^^ clines. With reports by Davies et al. (1962) and articles by Wallman and Hilton (1962) and Witkop and Wolf (1963) this complication of tetracycline therapy became widely recognized. FIG 1. Tetracycline staining and hypoplasia of the permanent Hypoplasia of enamel of the primary dentition asso- anterior teeth.
    [Show full text]
  • Prednisolone / Neomycin / Tetracycline For- Mulation
    SAFETY DATA SHEET Prednisolone / Neomycin / Tetracycline For- mulation Version Revision Date: SDS Number: Date of last issue: 23.03.2020 5.5 25.08.2020 407516-00013 Date of first issue: 07.01.2016 SECTION 1. PRODUCT AND COMPANY IDENTIFICATION Product name : Prednisolone / Neomycin / Tetracycline Formulation Manufacturer or supplier's details Company name of supplier : MSD Address : 2000 Galloping Hill Road Kenilworth - New Jersey - U.S.A. 07033 Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000 E-mail address : [email protected] Recommended use of the chemical and restrictions on use Recommended use : Veterinary product SECTION 2. HAZARDS IDENTIFICATION GHS Classification Skin sensitization : Category 1 Reproductive toxicity : Category 1A Effects on or via lactation Specific target organ toxicity : Category 2 (Kidney, inner ear) - repeated exposure Specific target organ toxicity : Category 2 (Gastrointestinal tract, Nervous system, Skin, Teeth) - repeated exposure (Oral) GHS label elements Hazard pictograms : Signal Word : Danger Hazard Statements : H317 May cause an allergic skin reaction. H360D May damage the unborn child. H362 May cause harm to breast-fed children. H373 May cause damage to organs (Kidney, inner ear) through prolonged or repeated exposure. H373 May cause damage to organs (Gastrointestinal tract, Nervous system, Skin, Teeth) through prolonged or repeated exposure if swallowed. Precautionary Statements : Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. 1 / 24 SAFETY DATA SHEET Prednisolone / Neomycin / Tetracycline For- mulation Version Revision Date: SDS Number: Date of last issue: 23.03.2020 5.5 25.08.2020 407516-00013 Date of first issue: 07.01.2016 P260 Do not breathe dust.
    [Show full text]
  • Evaluating Risks from Antibacterial Medication Therapy
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations Summer 2010 Evaluating Risks from Antibacterial Medication Therapy Sharon B. Meropol University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Therapeutics Commons Recommended Citation Meropol, Sharon B., "Evaluating Risks from Antibacterial Medication Therapy" (2010). Publicly Accessible Penn Dissertations. 424. https://repository.upenn.edu/edissertations/424 A version of Chapter 3 has been published: Meropol SB, Chen Z, Metlay JP. Reduced antibiotic use for acute respiratory infections in adults and children. Br J Gen Prac. Oct. 2009; 59(567)3321-328.DOI:10.3399/ bjgp09X472610. E321-328 PMID: 19843412 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/424 For more information, please contact [email protected]. Evaluating Risks from Antibacterial Medication Therapy Abstract ABSTRACT EVALUATING RISKS FROM ANTIBACTERIAL MEDICATION THERAPY USING AN OBSERVATIONAL PRIMARY CARE DATABASE Sharon B. Meropol Joshua P. Metlay Virtually everyone in the U.S. is exposed to antibacterial drugs at some point in their lives. It is important to understand the benefits and risks elatedr to these medications with nearly universal public exposure. Most information on antibacterial drug-associated adverse events comes from spontaneous reports. Without an unexposed control group, it is impossible to know the real risks for treated vs. untreated patients. We used an electronic medical record database to select a cohort of office visits for non-bacterial acuteespir r atory tract infections (excluding patients with pneumonia, sinusitis, or acute exacerbations of chronic bronchitis), and compared outcomes of antibacterial drug-exposed vs.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Spironolactone Information Sheet
    Spironolactone Information Sheet Spironolactone has been used off-license in women with acne for over 30 years due to its anti-androgenic properties and is included in American Guidelines for acne. However, although widely used by some dermatologists in the UK, there is little convincing trial evidence of its benefit. What dose of spironolactone is prescribed for adult female acne? SAFA participants are prescribed spironolactone (or placebo) 50mg once daily for 6 weeks, increased to 100mg once daily for a further 18 weeks if tolerated. Effectiveness of treatment is judged after 12 weeks. The reason for dose escalation is to avoid side effects from spironolactone, which can cause gastro-intestinal disturbances, dizziness, gynaecomastia and menstrual disturbances, particularly at higher doses. Is potassium and renal monitoring required? 1 American guidelines and large UK-based observational datasets suggest that, providing a baseline renal function test is normal then no further monitoring is required. All participants in the SAFA trial have renal function tests, including potassium, carried out at baseline, so do not need further blood testing. Is spironolactone teratogenic? Spironolactone should be avoided in pregnancy but risk of harm to the foetus is thought to be less high than 1,2 for other oral acne treatments, such as tetracycline antibiotics, co-cyprindiol and oral isotretinoin. Pregnancy risk relates to feminisation of the male foetus in the last trimester. Pregnancy tests are carried out at baseline in the SAFA trial and participants of child-bearing potential at risk of pregnancy are advised they must use effective contraception. Why isn’t spironolactone used for men with acne? A small study found that a many young men with acne who were treated with spironolactone experienced breast enlargement and the trial was stopped early.
    [Show full text]
  • Antibiotics and Antibiotic Resistance
    This is a free sample of content from Antibiotics and Antibiotic Resistance. Click here for more information on how to buy the book. Index A Antifolates. See also specific drugs AAC(60)-Ib-cr, 185 novel compounds, 378–379 ACHN-975 overview, 373–374 clinical studies, 163–164 resistance mechanisms medicinal chemistry, 166 sulfamethoxazole, 378 structure, 162 trimethoprim, 374–378 AcrAB-TolC, 180 Apramycin, structure, 230 AcrD, 236 Arbekacin, 237–238 AdeRS, 257 Avibactam, structure, 38 AFN-1252 Azithromycin mechanism of action, 148, 153 resistance, 291, 295 resistance, 153 structure, 272 structure, 149 Aztreonam, structure, 36 AIM-1, 74 Amicoumacin A, 222 Amikacin B indications, 240 BaeSR, 257 structure, 230 BAL30072, 36 synthesis, 4 BB-78495, 162 Aminoglycosides. See also specific drugs BC-3205, 341, 344 historical perspective, 229–230 BC-7013, 341, 344 indications, 239–241 b-Lactamase. See also specific enzymes mechanism of action, 232 classification novel drugs, 237 class A, 67–71 pharmacodynamics, 238–239 class B, 69–74 pharmacokinetics, 238–239 class C, 69, 74 resistance mechanisms class D, 70, 74–77 aminoglycoside-modifying enzymes evolution of antibiotic resistance, 4 acetyltransferases, 233–235 historical perspective, 67 nucleotidyltransferases, 235 inhibitors phosphotransferases, 235 overview, 37–39 efflux-mediated resistance, 236 structures, 38 molecular epidemiology, 236–237 nomenclature, 67 overview, 17, 233 b-Lactams. See also specific classes and antibiotics ribosomal RNA modifications, 235–236 Enterococcus faecium–resistancemechanisms,
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from Treatment of stable chronic obstructive pulmonary disease: a protocol for a systematic review and evidence map Journal: BMJ Open ManuscriptFor ID peerbmjopen-2018-027935 review only Article Type: Protocol Date Submitted by the 15-Nov-2018 Author: Complete List of Authors: Dobler, Claudia; Mayo Clinic, Evidence-Based Practice Center, Robert D.
    [Show full text]